Table 1.
Demographics and clinical characteristics of COVID-19 survivors with SARDs who provided survey data (n=174).
| Age at time of survey in years, mean ± SD | 52 ± 16 |
| Female, n (%) | 140 (81) |
| Race, n (%) | |
| White | 139 (80) |
| Black | 17 (10) |
| Asian | 9 (5) |
| Other | 7 (4) |
| Hispanic or Latinx ethnicity, n (%) | 18 (10) |
| Smoking status*, n (%) | |
| Never | 125 (72) |
| Past | 47 (27) |
| Current | 1 (<1) |
| Type of SARD**, n (%) | |
| Rheumatoid arthritis | 69 (40) |
| Systemic lupus erythematosus | 25 (14) |
| Psoriatic arthritis | 21 (12) |
| Sjogren’s syndrome | 10 (6) |
| Axial spondyloarthritis | 9 (5) |
| Polymyalgia rheumatica | 8 (5) |
| ANCA-associated vasculitis | 6 (3) |
| Mixed connective tissue disease | 5 (3) |
| Inflammatory myositis | 3 (2) |
| Juvenile idiopathic arthritis | 3 (2) |
| Systemic sclerosis | 2 (1) |
| Sarcoidosis | 2 (1) |
| Baseline glucocorticoid use at COVID-19 onset, n (%) | 29 (18) |
| Dose in daily mg of prednisone equivalents, median [IQR] | 9.5 [5, 13.5] |
| Comorbidities***, n (%) | |
| Obesity | 39 (22) |
| Hypertension | 35 (20) |
| Asthma | 25 (14) |
| Obstructive sleep apnea | 16 (9) |
| Coronary artery disease | 12 (7) |
| Diabetes | 11 (6) |
| Heart failure | 5 (3) |
| Chronic kidney disease | 5 (3) |
| Chronic obstructive pulmonary disease | 3 (2) |
| Interstitial lung disease/pulmonary fibrosis | 3 (2) |
| Solid tumor | 3 (2) |
| Comorbidity count#, median [IQR] | 1 [0, 2] |
ANCA, anti-neutrophil cytoplasmic antibody; COVID-19, coronavirus disease 2019; IQR, interquartile range; SARD, systemic autoimmune rheumatic disease; SD, standard deviation.
*
Smoking status was missing for 1 participant.
**
Other SARDs included IgG4-related disease, undifferentiated connective tissue disease, giant cell arteritis (each n=1).
***
Other comorbidities included peptic ulcer disease, pulmonary hypertension, stroke, and dementia (each n=2).
#
Defined as the sum of comorbidities assessed in the survey.